As of November 14, 2026, Idexx Laboratories Inc /De has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 13, 2026 to March 26, 2026 (Form 8-K, March 26, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Idexx Laboratories Inc /De? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-03-26
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-02-13
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-01-13
Idexx Laboratories Inc /De reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-13 to 2026-03-26. Every row below is cited to the filing it comes from, and this page adds each new change as Idexx Laboratories Inc /De files it.
Also on the record for Idexx Laboratories Inc /De
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 30, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.04% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 7.51% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs Idexx Laboratories Inc /De now and the warning signs.
Free to see. No signup.
Keep reading
More on Idexx Laboratories Inc /De and the records around it.
Companies that share a holder
- Vanguard Portfolio Management also filed stake reports on 941 other companies: Newmark Group Inc (Nov 2026), A10 Networks Inc (Oct 2026), ADT Inc (Oct 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
- The Vanguard Group also filed stake reports on 2385 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Idexx Laboratories Inc /De
Get an email when Idexx Laboratories Inc /De files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Idexx Laboratories Inc /De?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Idexx Laboratories Inc /De: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Idexx Laboratories Inc /De covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-26 | Reported | not named in the filing | 8-K, 2026-03-26 | ||
| 2026-02-13 | Reported | not named in the filing | 8-K, 2026-02-13 | ||
| 2026-01-13 | Reported | not named in the filing | 8-K, 2026-01-13 |
New leaders reset buying decisions — get the Full Report on Idexx Laboratories Inc /De: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Idexx Laboratories Inc /De, with the record behind each one.
Find candidates like senior executive at Idexx Laboratories Inc /DeEvery change, in the filing's words
Reported
On March 24, 2026, IDEXX Laboratories, Inc. ("IDEXX") and Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, mutually agreed that Dr. Hunt will cease serving in her current role effective on April 13, 2026 (the "Separation Date") and will continue to provide advisory services on an as-needed basis until July 13, 2026 (the "Final Employment Date").
- IDEXX and Dr. Hunt entered into a separation letter agreement (the "Separation Agreement") to memorialize the terms of Dr. Hunt's advisory role and subsequent departure.
- Vesting of stock option, restricted stock unit and performance stock unit awards previously issued to Dr. Hunt under IDEXX's stock incentive plans will cease effective as of the Final Employment Date, and all unvested awards will be forfeited.
- Dr. Hunt's stock option awards, to the extent vested and exercisable, will remain exercisable during the period following the Final Employment Date that is specified in the applicable award agreements.
- Dr. Hunt's position with IDEXX is being eliminated, and, as a result, IDEXX deems Dr. Hunt's separation to be a termination of employment without cause for purposes of determining Dr. Hunt's separation benefits.
- The Separation Agreement also contains a general release of claims in favor of IDEXX (including a reaffirmation thereof on or following the Separation Date and on or following the Final Employment Date), non-disparagement and continuing cooperation covenants and an acknowledgement by Dr. Hunt that she continues to be bound by restrictive covenants applicable to her under the Confidential Information, Work Product, and Restrictive Covenant Agreement between her and IDEXX dated January 24, 2022.
Reported
(b) On February 13, 2026, Ms. M. Anne Szostak provided IDEXX Laboratories, Inc. (the "Company") notice of her intention to retire from the Board of Directors (the "Board") effective immediately following the Company's 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting") to be held on May 12, 2026.
- Ms. Szostak's decision to retire from the Board does not arise from any disagreement with the Company or the Board on any matter relating to the Company's operations, policies, practices or otherwise.
- The Company thanks Ms. Szostak for her extraordinary service, contributions and leadership during her tenure as a member of the Board since 2012.
Reported
On January 11, 2026, Jonathan (Jay) Mazelsky notified IDEXX Laboratories, Inc. (the "Company" or "IDEXX") of his intent to step down as the Company's President and Chief Executive Officer effective as of May 12, 2026 (the "Transition Date") and retire from the Company and the Company's Board of the Directors (the "Board") immediately following the Company's annual meeting of shareholders in May 2027 (the "Retirement Date").
- On January 13, 2026, the Company announced that effective as of the Transition Date Mr. Mazelsky will transition to the role of Executive Chair of the Board and Michael (Mike) Erickson, PhD, will assume the role of President and Chief Executive Officer of the Company and join the Board as a Class II Director.
- In his capacity as President and Chief Executive Officer, Dr. Erickson will serve as the Company's principal executive officer.
- Mr. Mazelsky will work closely with Dr. Erickson until Mr. Mazelsky's Retirement Date to support a seamless transition.
- Mr. Lawrence D. Kingsley, currently serving as the Board's independent Non-Executive Chair, will serve as independent Lead Director effective as of the Transition Date.
- Dr. Erickson, 52, brings nearly two decades of leadership experience and significant healthcare technology and innovation expertise.
- Since joining IDEXX in 2011, he has held senior positions across key portions of the Company's business, including diagnostics, software, strategy and corporate accounts, and currently serves as Executive Vice President and General Manager of IDEXX's Global Point of Care Diagnostics and Telemedicine lines of business.
- Prior to joining the Company, Dr. Erickson advised leading pharmaceutical, biotechnology and health service companies as an Associate Principal at McKinsey & Company.
Tools for this story
Each opens in a new tab, filled in for Idexx Laboratories Inc /De. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
